Funder: National Institutes of Health
Due Dates: February 25, 2027 (Applications) | June 25, 2027 (Applications) | October 25, 2027 (Applications)
Funding Amounts: No budget limit; requests must reflect project needs; up to five years
Summary: Supports multidisciplinary drug and device discovery, preclinical development, and early human testing for mental disorders.
Key Information: Requires two to three research projects and one Administrative Core; single-project proposals should use the companion U01 opportunity.
Description
This NIH U19 cooperative agreement, administered by the National Institute of Mental Health (NIMH), supports multidisciplinary groups developing innovative therapeutics and research tools. It funds discovery, preclinical development, early human studies, and proof-of-concept testing of rationally based candidate agents and neurostimulation approaches. The Grants.gov listing also identifies substance use disorders and alcohol use disorder within the program’s scope.
Research interests include novel molecular and neural-circuit targets, ligands and imaging probes, neuromodulation technologies, and biotechnology products such as biologics, gene-based therapies, cell therapies, and microbiome therapies. The program aims to accelerate treatment development and validate tools for experimental therapeutics, particularly where medical needs remain unmet. Academia–industry and public–private partnerships are strongly encouraged.
